Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 27, 2007--Idera Pharmaceuticals, Inc. (Amex: IDP) today announced the election of Hans Mueller, Ph.D., to the Company's Board of Directors. Dr. Mueller was elected as a class I director for a term expiring at the Company's annual meeting in 2008.

Dr. Mueller most recently served as Senior Vice President of Global Business Development at Wyeth Pharmaceuticals, where he played a key role in leading world-wide licensing, partnerships, collaborations, and divestitures. Since retiring in 2004, Dr. Mueller has consulted for a number of private life science companies.

"Idera is pleased to welcome Dr. Mueller to the Board of Directors as we advance our two lead TLR-targeted drug candidates, IMO-2055 and IMO-2125, in the clinic," said James B. Wyngaarden, M.D., Chairman of Idera's Board of Directors. "Dr. Mueller brings to Idera extensive experience in the pharmaceutical and biotechnology industries having managed and negotiated numerous transactions and having a central role in various public and private equity and partnership transactions."

"I look forward to working with Idera and to providing strategic guidance that will help Idera discover and develop TLR-targeted drug candidates for unmet medical needs," said Dr. Mueller.

Dr. Hans Mueller received a Ph.D. in Actuarial Sciences and Mathematical Statistics from the University of Bern, Switzerland and is a graduate of Harvard Business School's Advanced Management Program. From 1969-1985, he held roles with increasing levels of responsibility at Sandoz, now part of Novartis, in the areas of research, regulatory affairs, manufacturing, systems development, new product planning, licensing and business development. From 1985-1993, Dr. Mueller served as Executive Vice President, President and Chief Executive Officer of Nova Pharmaceutical Corporation, now part of Scios, Inc. He currently serves on the Board of Directors for Othera Pharmaceuticals and TransMolecular, Inc. and previously served on the Board of Directors for SCOLR Pharma, Inc. and Hypnion, Inc. Dr. Mueller is also an Advisory Board member for Easton Capital.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use as vaccine adjuvants. Idera's proprietary drug candidates are designed to modulate specific TLRs, which are a family of immune system receptors. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. Idera's most advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial in oncology and in a Phase 1/2 chemotherapy combination trial in oncology. Idera's second TLR9 agonist, IMO-2125, is currently in a Phase 1 trial for the treatment of hepatitis C virus infection. Idera is collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications. Idera is also collaborating with Merck & Co., Inc. for the use of Idera's TLR7, 8 and 9 agonists in combination with Merck's therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer's disease. For more information, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether results obtained in early clinical studies or in preclinical studies will be indicative of results obtained in future clinical trials or warrant additional trials; whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations with Novartis and Merck will be successful; whether Idera's cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q filed on August 1, 2007, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

    CONTACT: Idera Pharmaceuticals, Inc.
             Kelly Luethje, 617-679-5519
             kluethje@iderapharma.com
             or
             MacDougall Biomedical Communications
             Chris Erdman, 508-647-0209
             cerdman@macbiocom.com

    SOURCE: Idera Pharmaceuticals, Inc.